Third Rock Ventures V, L.P. bought RAPP
October 30, 2026 · Form 4 insider transaction
Third Rock Ventures V, L.P. bought 238,095 shares of Rapport Therapeutics, Inc. at $21.00 per share, a transaction worth $5.00M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Shares acquired in a private placement pursuant to a Securities Purchase Agreement dated October 28, 2026 by and between the Issuer, Third Rock Ventures V, L.P. ("TRV V") and Third Rock Ventures VI, L.P. ("TRV VI").; These shares are directly held by TRV V. The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.; Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.